ARGX-117

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Multifocal Motor Neuropathy

Conditions

Multifocal Motor Neuropathy

Trial Timeline

Mar 31, 2022 → Jun 4, 2024

NCT ID

NCT05225675

About ARGX-117

ARGX-117 is a phase 2 stage product being developed by Argenx for Multifocal Motor Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05225675. Target conditions include Multifocal Motor Neuropathy.

What happened to similar drugs?

0 of 1 similar drugs in Multifocal Motor Neuropathy were approved

Approved (0) Terminated (0) Active (1)

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05907096	Phase 2	Active	Feb 17, 2024	Jul 31, 2026	Delayed Graft Function
NCT05405361	Phase 2	Active	Jan 18, 2023	Sep 30, 2029	Multifocal Motor Neuropathy (MMN)
NCT05225675	Phase 2	Completed	Mar 31, 2022	Jun 4, 2024	Multifocal Motor Neuropathy

Competing Products

7 competing products in Multifocal Motor Neuropathy

See all competitors

Product	Company	Stage	Hype Score
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
Vivaglobin	CSL	Phase 2	35
ARGX-117	Argenx	Phase 2	36
Empasiprubart + IVIG (Intravenous Immunoglobulin)	Argenx	Phase 3	44
mefloquine	Biogen	Phase 1/2	21
Tysabri	Biogen	Pre-clinical	23
HyQvia + Subcuvia	Baxter	Phase 2	32